[an error occurred while processing this directive]|[an error occurred while processing this directive]
新型冠状病毒病疫情期间乳腺癌患者的术后辅助放疗
房辉, 王淑莲, 李晔雄
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科 100021
Strategies of adjuvant radiotherapy for patients with breast cancer in COVID-19 disease outbreak
Fang Hui, Wang Shulian, Li Yexiong
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Abstract：Breast cancer is the most common malignancy in women in China, and adjuvant radiotherapy is an important component of multidisciplinary treatment. The 2019 novel coronavirusdisease(COVID-19) poses a significant challenge for patients to complete radiotherapy, because of a high hospital-related transmission rate of COVID-19 and a high risk of severe events for cancer patients. In this comment, we propose three major strategies for adjuvant radiotherapy in this COVID-19 outbreak:omission of radiotherapy, postponing of radiotherapy, and hypofractionated radiotherapy.
Fang Hui,Wang Shulian,Li Yexiong. Strategies of adjuvant radiotherapy for patients with breast cancer in COVID-19 disease outbreak[J]. Chinese Journal of Radiation Oncology, 2020, 29(5): 321-323.
[1] Wang DW, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China[J]. JAMA,2020,(published onlineFeb 7). DOI:10.1001/jama.2020.1585.
[2] Liang WH, Guan WJ, Chen RC, et al. Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China[J]. Lancet Oncol,2020,(published onlineFeb 14). DOI:10.1016/S1470-2045(20)30096-6.
[3] Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer:long-term follow-up of CALGB 9343[J]. Jclin oncol,2013,31(19):2382-2387. DOI:10.1200/JCO.2012.45.2615.
[4] Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIMEⅡ):a randomised controlled trial[J]. Lancet Oncol,2015,16(3):266-273. DOI:10.1016/S1470-2045(14)71221-5.
[5] McCormick B, Winter K, Hudis C, et al. RTOG 9804:a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation[J]. J Clin Oncol,2015,33(7):709-715. DOI:10.1200/JCO.2014.57.9029.
[6] Muhsen S, Moo TA, Patil S, et al. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy[J]. Ann Surg Oncol,2018,25(7):1912-1920. DOI:10.1245/s10434-018-6422-9.
[7] Hershman DL, Wang X, McBride R, et al. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival[J]. Int J Radiat Oncol Biol Phys,2006,65(5):1353-1360. DOI:10.1016/j.ijrobp.2006.03.048.
[8] Shurell E, Olcese C, Patil S, et al. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ[J]. Cancer,2018,124(1):46-54. DOI:10.1002/cncr.30972.
[9] Olivotto IA, Lesperance ml, Truong PT, et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy[J]. J Clin Oncol,2009,27(1):16-23. DOI:10.1200/JCO.2008.18.1891.
[10] van Maaren MC, Bretveld RW, Jobsen JJ, et al. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival[J]. Br J Cancer,2017,117(2):179-188. DOI:10.1038/bjc.2017.159.
[11] Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial):5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial[J]. Lancet,2017,390(10099):1048-1060. DOI:10.1016/S0140-6736(17)31145-5.
[12] Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast:Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline[J]. PractRadiatoncol,2018,8(3):145-152. DOI:10.1016/j.prro.2018.01.012.
[13] Wang SL, Li YX. Moderately hypofractionated breast radiation therapy:is more evidence needed?-Authors′ reply[J]. Lancet Oncol,2019,20(5):e227. DOI:10.1016/S1470-2045(19)30233-5.
[14] Marta GN, Poortmans P. Moderately hypofractionated breast radiation therapy:is more evidence needed?[J]. Lancet Oncol,2019,20(5):e226. DOI:10.1016/S1470-2045(19)30078-6.
[15] Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer:a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol,2019,20(3):352-360. DOI:10.1016/S1470-2045(18)30813-1.
2020, Vol. 29 
